Exploring curcumin's role in easing irritability in kids with autism

Not Applicable

Completed

• Conditions: Autism spectrum disorder; Mental and Behavioural Disorders

• Registration Number: ISRCTN13881401
• Lead Sponsor: Roozbeh Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2023-05-01
• Study Start: 2023-11-23
• Last Update Posted: 4 December 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Children aged 4–12 years
2. Male or female
3. Outpatients referred to clinic with probable autistic signs and symptoms and who meet the DSM-5 criteria

Exclusion Criteria

1. Concurrent prominent psychiatric disorder
2. Preexisting medical conditions (in particular epileptic disorders and febrile seizures)
3. Intellectual disability (IQ <70)
4. History of drug or alcohol abuse
5. History of tardive dyskinesia
6. History of taking antipsychotic medication within 6 months prior to enrollment

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Irritability is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12

Secondary Outcome Measures

Name	Time	Method
<br> 1. Lethargy/social withdrawal is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12<br> 2. Stereotypic behavior is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12<br> 3. Inappropriate speech is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12<br> 4. Hyperactivity/noncompliance is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12<br>